Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Share-based Compensation (2019 - 2025)

Korro Bio's Share-based Compensation history spans 7 years, with the latest figure at $2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 52.62% year-over-year to $2.1 million, compared with a TTM value of $7.7 million through Dec 2025, up 71.56%, and an annual FY2025 reading of $7.7 million, up 71.56% over the prior year.
  • Share-based Compensation for Q4 2025 was $2.1 million at Korro Bio, up from $1.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $6.1 million in Q2 2021, with the low at -$14.3 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $1.8 million recorded in 2025.
  • Year-over-year, Share-based Compensation plummeted 376.63% in 2022 and then soared 215.1% in 2024.
  • Tracing KRRO's Share-based Compensation over 5 years: stood at $5.2 million in 2021, then plummeted by 376.63% to -$14.3 million in 2022, then skyrocketed by 108.59% to $1.2 million in 2023, then rose by 10.59% to $1.4 million in 2024, then skyrocketed by 52.62% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Share-based Compensation are $2.1 million (Q4 2025), $1.8 million (Q3 2025), and $2.0 million (Q2 2025).